ChemoCentryx Announces FDA Acceptance of the Avacopan New Drug Application (NDA) for the Treatment of ANCA-Associated Vasculitis
— FDA sets PDUFA goal date of July 7, 2021 —MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: […]